Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Natera Inc. Common Stock — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.61 (market cap $753.07M), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 75.7× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 57 Days and Natera Inc. Common Stock for 0 Days on average.
| FEPI | NTRA | |
|---|---|---|
Market Cap | $753.07M | $57.03B |
Volume | 329,956 | 1,131,157 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $425.64 |
52-Week Low | $37.98 | $179.42 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.28, showing minimal daily movement with a 0.14% gain. The ETF employs a covered call strategy on AI and mega-cap tech stocks, generating substantial weekly dividends averaging $0.20-0.21 per distribution. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The fund's high-yield approach provides consistent income but faces challenges in total return performance compared to peers.
FEPI offers investors a high-yield income stream through its covered call strategy, currently yielding approximately 25%. However, the fund's concentrated tech exposure and capped upside potential present significant risks during market volatility. While the weekly dividend structure appeals to income-focused investors, total return underperformance and dependence on tech sector stability warrant careful consideration for long-term positioning.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
